Compare Citius Pharmaceuticals Inc (CTXR) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GameStop Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while GameStop Corp. trades at $18.54 (market cap $8.44B). The key difference: GameStop Corp. is far larger — about 421.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| CTXR | GME | |
|---|---|---|
Market Cap | $20.01M | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $27.69 |
52-Week Low | $0.48 | $18.79 |
Enterprise Value | $16.23M | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
GME trades at $18.605, down 0.98% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 beating expectations of $0.16. Revenue for 2025 was $3.82B, with net income of $131.3M and a profit margin of 3.43%. Recent news highlights a potential shift from a $56B eBay takeover bid to a partnership, as reported by Bloomberg on August 10, 2026.
The outlook is mixed: strong profitability improvements and debt reduction support upside, but analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution of strategic partnerships, competitive pressures in retail, and shareholder dilution from recent debt-for-stock swaps. The stock's valuation appears reasonable with a P/E of 14.04, but sentiment remains divided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
